gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Single-nucleotide polymorphism (SNP) of ABCB1 transporter in colorectal cancer patients and relation to the pharmacokinetics of irinotecan

Meeting Abstract

  • corresponding author presenting/speaker Katrin Farker - Institut für Klinische Pharmakologie, Universitätsklinikum Jena, Deutschland
  • Ute Merkel - Institut für Klinische Pharmakologie, Universitätsklinikum Jena
  • Ulrich Wedding - Klinik für Innere Medizin II, Universitätsklinikum Jena
  • Marion Hippius - Institut für Klinische Pharmakologie, Universitätsklinikum Jena
  • Klaus Höffken - Klinik für Innere Medizin II, Universitätsklinikum Jena
  • Annemarie Hoffmann - Institut für Klinische Pharmakologie, Universitätsklinikum Jena

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPE229

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk339.shtml

Published: March 20, 2006

© 2006 Farker et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

P-glycoprotein, the protein product of human multidrug-resistance (ABCB1) gene, is an important efflux pump for many common drugs, including anticancer drugs like irinotecan, doxorubicin and paclitaxel. ABCB1 gene polymorphism may be also involved in modulating interindividual susceptibility to certain diseases. In an ongoing project supported by German Cancer Aid (grant AZ-70-2445-Hö3) we studied a major known single nucleotide polymorphism (C3435T in Exon 26) in 67 patients. The detected genotype variant frequencies were as follows: CC in 28.4%, CT in 46.3 %, and TT in 25.4%. The frequency of the C- allele (51.5%) and of the genotypes were comparable to reported data of white subjects in Western Europe. In 18 patients we investigated the pharmacokinetics of irinotecan. We did not identify correlations between genotypes of C3435T and AUC of irinotecan. Our findings suggest that studied ABCB1 polymorphism did not influence the systemic exposure of irinotecan in colorectal cancer patients.